

9574 - Identification of patients at high risk for relapse using the Merlin Assay (CP-GEP) in an independent cohort of 432 patients with stage I/II melanoma who did not undergo sentinel lymph node biopsy

Teresa Amaral^{1*}, Eftychia Chatziioannou^{1*}, Alica Nuebling¹, Lena Nanz¹, Tobias Sinnberg¹, Heike Niessner¹; Ulrike Leiter¹; Jvalini Dwarkasing², Tim Arentsen², Christian Groβ², Alexander Eggermont³; Lukas Flatz¹; Stephan Forchhammer¹

Background: Sentinel lymph node biopsy (SLNB) is the gold standard for nodal assessment in staging cutaneous melanoma (CM) according to AJCC v8. 80-85% of patients (pts) do not have nodal metastasis, but most pts who relapse or die from melanoma are initially diagnosed as 'low risk' early-stage. We showed that the clinicopathological-gene expression profiling (CP-GEP) model can stratify pts with negative SLNB for their risk of recurrence.

Aim: To demonstrate the ability of CP-GEP to stratify pts who did not undergo SLNB for their risk of recurrence in an expanded cohort.

Methods: formalin-fixed paraffin-embedded primary tumor samples of pts with CM diagnosed between 2000-2020 who did not undergo SLNB were analyzed. The CP-GEP model used combines the expression of 8 genes (**SERPINE2, GDF15, ITGB3, CXCL8, LOXL4, TGFBR1, PLAT and MLANA**) by qPCR with **age and Breslow thickness** to obtain a binary output: CP-GEP **Low-Risk** or **High-Risk**. Relapse-free survival (RFS), distant metastasis free survival (DMFS) and Melanoma Specific Survival (MSS) were evaluated using Kaplan-Meier curves. Median follow-up time was 5 years.

CP-GEP risk stratifies pts with early-stage melanoma who did not undergo SLNB based on their risk of recurrence. CP-GEP **Low-Risk** pts have a favorable long-term survival, while pts with CP-GEP **High-Risk** have a high risk of recurrence. This study shows the potential of CP-GEP to stratify pts with cutaneous melanoma beyond SLNB.

Correspondence: Teresa.amaral@med.uni-tuebingen.de

Table 1: Patients characteristics

n (%)			n (%)			n (%)			
Gender	Female	173 (40.0)	Stages	IA	346 (80.0)	Localization	Head & Neck	85 (19.7)	
	Male	259 (60.0)		IB	73 (16.9)		Trunk	200 (46.3)	
Ulceration	Absent	417 (96.5)	IIA	5 (1.2)	Upper Extremities	66 (15.3)	Histologic type	Superficial spreading	310 (71.8)
	Present	15 (3.5)	IIB	1 (0.2)	Lower Extremities	80 (18.5)		Nodular	3 (0.7)
CP-GEP	Low-risk	416 (96.3)	IIC	7 (1.6)	T-categories	T1a	346 (80.0)	Lentigo maligna	82 (19.0)
	High-risk	16 (3.7)	T1b	60 (13.9)	T2a	13 (3.0)	Acral lentiginous	23 (5.3)	
Age (years)	Median [1QR, 3QR]	63 (50, 75)	T2b	1 (0.2)	T3a	4 (0.9)	Other	7 (1.6)	
Breslow (mm)	Median [1QR-3QR]	0.50 (0.40, 0.70)	T3b	0 (0.0)	T4a	1 (0.2)			
			T4b	7 (1.6)					

Figure 2: 5 years RFS, DMFS, and MSS stratified by CP-GEP as **Low-Risk** or **High-Risk**




Table 2: 5 years survival rates according to CP-GEP **Low-Risk** or **High-Risk**

	N	#RFS events	5-years RFS, 95%CI	#DMFS events	5-years DMFS, 95%CI	#MSS events	5-years MSS, 95%CI
Complete Cohort	432	17	94.4 [91-96.5]	8	97.5 [95.1-98.8]	6	98.1 [95.8-99.1]
CP-GEP Low Risk	416	10	96.6 [93.6-98.2]	3	99 [96.9-99.7]	1	99.7 [97.8-100]
CP-GEP High Risk	16	7	23.4 [3.6-53.2]	5	43.9 [11.7-73]	5	42.2 [11.1-71.3]

Figure 1: Generation of the study cohort

